Methadone in Cystectomy Patients (METAMORF)
Pain, Postoperative, Postoperative Complications, Pathologic Processes
About this trial
This is an interventional treatment trial for Pain, Postoperative focused on measuring morphine, methadone, analgesics, opioids, effect of drugs
Eligibility Criteria
Inclusion Criteria:
- All patients (≥18 years) scheduled for elective robot assisted cystectomy.
Exclusion Criteria:
- American Society of Anesthesiologists (ASA) physical status IV or V
- Prolonged QTc-interval assessed by electrocardiogram (> 440 milliseconds)
- Existing treatment with a high risk of QTc-interval prolongation
- Allergy to study drugs
- Preoperative daily use of opioids
- Inability to provide informed consent
- Severe respiratory insufficiency (oxygen treatment at home)
- Heart failure (ejection fraction < 30%)
- Acute abdominal pain
- Signs of severe liver dysfunction (cirrhosis, inflammation/hepatitis or liver malignancy)
- Severe kidney insufficiency (estimated Glomerular Filtration Rate < 30 ml/min)
- Treatment with rifampicin
- Phaeochromocytoma
- Treatment with MAO-inhibitor during the last 14 days
- Pregnancy
- Nursing mothers
- Intraoperative conversion to open surgery (secondary inclusion criterion)
- Epidural analgesia in relation to surgical procedure
Sites / Locations
- Aarhus University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Methadone
Morphine
A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.
A 10 ml syringe with 2 mg/ml of morphine will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.